To confirm the inhibitory effect of Meds433 on GPT1, the mRNA level of GPT1 in CML CD34+-treated cells was measured and a significant down-modulation was seen (Fig. 6D). Here, GPT is linked to chronic myelogenous leukemia, BCR-ABL1 positive.